Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.

P. Y. Kwo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sixty percent of patients fail to respond to interferon monotherapy. African-Americans with hepatitis C appear to respond less well to interferon monotherapy. Retreatment with a higher dose of consensus interferon for 48 weeks has led to a sustained virologic response rate of 13%. As a group, interferon nonresponders who breakthrough while on interferon monotherapy seem to have a more favorable response rate to a repeat course of treatment. Retreatment with interferon and ribavirin for 6 months in nonresponders led to a sustained virologic response rate of 21%. Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders.

Original languageEnglish
Pages (from-to)11-17
Number of pages7
JournalCurrent Gastroenterology Reports
Volume2
Issue number1
StatePublished - Feb 2000

Fingerprint

Chronic Hepatitis C
Interferons
Retreatment
Therapeutics
Ribavirin
Hepatitis C
African Americans
Maintenance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of chronic hepatitis C in nonresponders to interferon monotherapy. / Kwo, P. Y.

In: Current Gastroenterology Reports, Vol. 2, No. 1, 02.2000, p. 11-17.

Research output: Contribution to journalArticle

@article{85d9428962184f058469e61cc9d528fc,
title = "Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.",
abstract = "Sixty percent of patients fail to respond to interferon monotherapy. African-Americans with hepatitis C appear to respond less well to interferon monotherapy. Retreatment with a higher dose of consensus interferon for 48 weeks has led to a sustained virologic response rate of 13{\%}. As a group, interferon nonresponders who breakthrough while on interferon monotherapy seem to have a more favorable response rate to a repeat course of treatment. Retreatment with interferon and ribavirin for 6 months in nonresponders led to a sustained virologic response rate of 21{\%}. Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders.",
author = "Kwo, {P. Y.}",
year = "2000",
month = "2",
language = "English",
volume = "2",
pages = "11--17",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.

AU - Kwo, P. Y.

PY - 2000/2

Y1 - 2000/2

N2 - Sixty percent of patients fail to respond to interferon monotherapy. African-Americans with hepatitis C appear to respond less well to interferon monotherapy. Retreatment with a higher dose of consensus interferon for 48 weeks has led to a sustained virologic response rate of 13%. As a group, interferon nonresponders who breakthrough while on interferon monotherapy seem to have a more favorable response rate to a repeat course of treatment. Retreatment with interferon and ribavirin for 6 months in nonresponders led to a sustained virologic response rate of 21%. Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders.

AB - Sixty percent of patients fail to respond to interferon monotherapy. African-Americans with hepatitis C appear to respond less well to interferon monotherapy. Retreatment with a higher dose of consensus interferon for 48 weeks has led to a sustained virologic response rate of 13%. As a group, interferon nonresponders who breakthrough while on interferon monotherapy seem to have a more favorable response rate to a repeat course of treatment. Retreatment with interferon and ribavirin for 6 months in nonresponders led to a sustained virologic response rate of 21%. Preliminary results from two trials in the United States demonstrate similar treatment efficacy. There is now evidence that maintenance interferon therapy may also be beneficial in interferon monotherapy nonresponders.

UR - http://www.scopus.com/inward/record.url?scp=0034136673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034136673&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 11

EP - 17

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -